159 related articles for article (PubMed ID: 33279497)
1. MiRNAs directly targeting the key intermediates of biological pathways in pancreatic cancer.
Sarwar A; Wang B; Su Q; Zhang Y
Biochem Pharmacol; 2021 Jul; 189():114357. PubMed ID: 33279497
[TBL] [Abstract][Full Text] [Related]
2. Role of microRNAs in the main molecular pathways of hepatocellular carcinoma.
Vasuri F; Visani M; Acquaviva G; Brand T; Fiorentino M; Pession A; Tallini G; D'Errico A; de Biase D
World J Gastroenterol; 2018 Jul; 24(25):2647-2660. PubMed ID: 29991871
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs as biomarkers and perspectives in the therapy of pancreatic cancer.
Xia T; Chen XY; Zhang YN
Mol Cell Biochem; 2021 Dec; 476(12):4191-4203. PubMed ID: 34324119
[TBL] [Abstract][Full Text] [Related]
4. Association between microRNAs and chemoresistance in pancreatic cancer: Current knowledge, new insights, and forthcoming perspectives.
Rahnama N; Jahangir M; Alesaeid S; Kahrizi MS; Adili A; Mohammed RN; Aslaminabad R; Akbari M; Özgönül AM
Pathol Res Pract; 2022 Aug; 236():153982. PubMed ID: 35779293
[TBL] [Abstract][Full Text] [Related]
5. miRNAs in insulin resistance and diabetes-associated pancreatic cancer: the 'minute and miracle' molecule moving as a monitor in the 'genomic galaxy'.
Chakraborty C; George Priya Doss C; Bandyopadhyay S
Curr Drug Targets; 2013 Sep; 14(10):1110-7. PubMed ID: 23834149
[TBL] [Abstract][Full Text] [Related]
6. Targeting miRNAs for pancreatic cancer therapy.
Shi M; Xie D; Gaod Y; Xie K
Curr Pharm Des; 2014; 20(33):5279-86. PubMed ID: 24479803
[TBL] [Abstract][Full Text] [Related]
7. MiR-1271 negatively regulates AKT/MTOR signaling and promotes apoptosis via targeting PDK1 in pancreatic cancer.
Xie F; Huang Q; Liu CH; Lin XS; Liu Z; Liu LL; Huang DW; Zhou HC
Eur Rev Med Pharmacol Sci; 2018 Feb; 22(3):678-686. PubMed ID: 29461595
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs in diabetic nephropathy: From molecular mechanisms to new therapeutic targets of treatment.
Yarahmadi A; Shahrokhi SZ; Mostafavi-Pour Z; Azarpira N
Biochem Pharmacol; 2021 Jul; 189():114301. PubMed ID: 33203517
[TBL] [Abstract][Full Text] [Related]
9. MiR-129 inhibits cell proliferation and metastasis by targeting ETS1 via PI3K/AKT/mTOR pathway in prostate cancer.
Xu S; Ge J; Zhang Z; Zhou W
Biomed Pharmacother; 2017 Dec; 96():634-641. PubMed ID: 29035829
[TBL] [Abstract][Full Text] [Related]
10. TRIM59 predicts poor prognosis and promotes pancreatic cancer progression via the PI3K/AKT/mTOR-glycolysis signaling axis.
Li R; Weng L; Liu B; Zhu L; Zhang X; Tian G; Hu L; Li Q; Jiang S; Shang M
J Cell Biochem; 2020 Feb; 121(2):1986-1997. PubMed ID: 31693252
[TBL] [Abstract][Full Text] [Related]
11. MicroRNAs associated with mitogen-activated protein kinase in human pancreatic cancer.
Ikeda Y; Tanji E; Makino N; Kawata S; Furukawa T
Mol Cancer Res; 2012 Feb; 10(2):259-69. PubMed ID: 22188669
[TBL] [Abstract][Full Text] [Related]
12. Luteolin mediated targeting of protein network and microRNAs in different cancers: Focus on JAK-STAT, NOTCH, mTOR and TRAIL-mediated signaling pathways.
Farooqi AA; Butt G; El-Zahaby SA; Attar R; Sabitaliyevich UY; Jovic JJ; Tang KF; Naureen H; Xu B
Pharmacol Res; 2020 Oct; 160():105188. PubMed ID: 32919041
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention.
Karmakar S; Kaushik G; Nimmakayala R; Rachagani S; Ponnusamy MP; Batra SK
Semin Cancer Biol; 2019 Feb; 54():63-71. PubMed ID: 29199014
[TBL] [Abstract][Full Text] [Related]
14. Identification of key microRNAs and their targets in exosomes of pancreatic cancer using bioinformatics analysis.
Zhao X; Ren Y; Cui N; Wang X; Cui Y
Medicine (Baltimore); 2018 Sep; 97(39):e12632. PubMed ID: 30278585
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.
Rachagani S; Macha MA; Heimann N; Seshacharyulu P; Haridas D; Chugh S; Batra SK
Adv Drug Deliv Rev; 2015 Jan; 81():16-33. PubMed ID: 25453266
[TBL] [Abstract][Full Text] [Related]
16. Emerging Role of mTOR Signaling-Related miRNAs in Cardiovascular Diseases.
Samidurai A; Kukreja RC; Das A
Oxid Med Cell Longev; 2018; 2018():6141902. PubMed ID: 30305865
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between miRNAs and signaling pathways involved in pancreatic cancer and pancreatic ductal adenocarcinoma.
Lotfi Z; Najjary S; Lotfi F; Amini M; Baghbanzadeh A; Rashid DJ; Asl ER; Baradaran B; Mokhtarzadeh A
Eur J Pharmacol; 2021 Jun; 901():174006. PubMed ID: 33711308
[TBL] [Abstract][Full Text] [Related]
18. microRNA-10b confers cisplatin resistance by activating AKT/mTOR/P70S6K signaling via targeting PPARγ in esophageal cancer.
Wu K; Hu Y; Yan K; Qi Y; Zhang C; Zhu D; Liu D; Zhao S
J Cell Physiol; 2020 Feb; 235(2):1247-1258. PubMed ID: 31267531
[TBL] [Abstract][Full Text] [Related]
19. microRNA-7 impairs autophagy-derived pools of glucose to suppress pancreatic cancer progression.
Gu DN; Jiang MJ; Mei Z; Dai JJ; Dai CY; Fang C; Huang Q; Tian L
Cancer Lett; 2017 Aug; 400():69-78. PubMed ID: 28450156
[TBL] [Abstract][Full Text] [Related]
20. EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K/AKT/mTOR signaling pathway.
Yan X; Hui Y; Hua Y; Huang L; Wang L; Peng F; Tang C; Liu D; Song J; Wang F
Biomed Pharmacother; 2019 Jan; 109():762-769. PubMed ID: 30551529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
